An Anti-Parkinson’s Disease Drug via Targeting Adenosine A2A Receptor Enhances Amyloid-β Generation and γ-Secretase Activity
Open Access
- 11 November 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (11) , e0166415
Abstract
γ-secretase mediates the intramembranous proteolysis of amyloid precursor protein (APP) and determines the generation of Aβ which is associated with Alzheimer’s disease (AD). Here we identified that an anti-Parkinson’s disease drug, Istradefylline, could enhance Aβ generation in various cell lines and primary neuronal cells of APP/PS1 mouse. Moreover, the increased generation of Aβ42 was detected in the cortex of APP/PS1 mouse after chronic treatment with Istradefylline. Istradefylline promoted the activity of γ-secretase which could lead to increased Aβ production. These effects of Istradefylline were reduced by the knockdown of A2AR but independent of A2AR-mediated G protein- or β-arrestin-dependent signal pathway. We further observed that A2AR colocalized with γ-secretase in endosomes and physically interacted with the catalytic subunit presenilin-1 (PS1). Interestingly, Istradefylline attenuated the interaction in time- and dosage-dependent manners. Moreover the knockdown of A2AR which in theory would release PS1 potentiated both Aβ generation and γ-secretase activity. Thus, our study implies that the association of A2AR could modulate γ-secretase activity. Istradefylline enhance Aβ generation and γ-secretase activity possibly via modulating the interaction between A2AR and γ-secretase, which may bring some undesired effects in the central nervous system (CNS).Keywords
Funding Information
- Ministry of Science and Technology of China (2015CB964502)
- Ministry of Science and Technology of China (2014CB964802)
- The National Natural Science Foundation of China (31371419)
- Science and Technology Commission of Shanghai Municipality (14DZ1900402)
This publication has 58 references indexed in Scilit:
- Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortexPsychopharmacology, 2013
- Istradefylline: First Global ApprovalDrugs, 2013
- Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activationNature, 2011
- Gamma-secretase activating protein is a therapeutic target for Alzheimer’s diseaseNature, 2010
- The 2.6 Angstrom Crystal Structure of a Human A2AAdenosine Receptor Bound to an AntagonistScience, 2008
- Correcting Confocal Acquisition to Optimize Imaging of Fluorescence Resonance Energy Transfer by Sensitized EmissionBiophysical Journal, 2004
- PS1 N- and C-terminal fragments form a complex that functions in APP processing and Notch signalingProceedings of the National Academy of Sciences, 2001
- Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and βAPP processingNature, 2000
- Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's diseaseNature, 1995
- Adenosine receptor-blocking xanthines as inhibitors of phosphodiesterase isozymesBiochemical Pharmacology, 1993